Altered Bone Mineral Density in Patients with Complete Androgen Insensitivity Syndrome

@article{Bertelloni1998AlteredBM,
  title={Altered Bone Mineral Density in Patients with Complete Androgen Insensitivity Syndrome},
  author={Silvano Bertelloni and Giampiero I. Baroncelli and Giovanni Federico and Marco Cappa and Roberto Lala and Giuseppe Saggese},
  journal={Hormone Research in Paediatrics},
  year={1998},
  volume={50},
  pages={309 - 314}
}
Androgens have major influences on the regulation of bone mineralization. Because of their unique peripheral metabolism androgens may act on bone via activation of the androgen and/or estrogen receptor. Patients with complete androgen insensitivity syndrome (cAIS) are natural models to assess androgen actions on bone. We studied bone mineral density (BMD) in 10 patients with cAIS (mean age 13.70, range 4.7–19.8 years); 3 patients were studied before gonadectomy; the others were castrated and 6… 

Figures and Tables from this paper

Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes.

TLDR
1) Androgens are of direct importance in the development and/or maintenance of BMD; and 2) testosterone and/ or low levels of dihydrotestosterone appear to be sufficient for BMD development and-or maintenance.

Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene

TLDR
Data suggest an important role for androgens in normal male growth and bone density not replaced by estrogens in patients with AIS with mutations in the androgen receptor (AR) gene.

Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads

TLDR
The maintenance of testes may represent a strategy to improve bone health in women with CAIS, but a strict follow-up to monitor the cancer risk is mandatory mainly from their 20s onwards.

The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome.

TLDR
It is concluded that even when compliance to exogenous estrogen use is excellent, women with complete AIS show moderate deficits in spine BMD, averaging close to 1 SD from normative means, and that with correction of BMD for bone size, skeletal deficits are magnified and include the proximal femur.

Case Report: Low Bone and Normal Lean Mass in Adolescents With Complete Androgen Insensitivity Syndrome

TLDR
These limited data indicate that adolescents with CAIS have bone mass deficit, and further studies are needed to understand the extent of BMD abnormalities and the effect of gonadectomy, especially early in childhood, and to establish the optimal HRT regimen for bone accrual.

Bone mineral density, body composition and metabolic profiles in adult women with complete androgen insensitivity syndrome and removed gonads using oral or transdermal estrogens.

TLDR
The results reinforce the importance of adequate hormonal treatment in women living with CAIS, suggesting a better effect from the transdermal route over the oral route.

Anthropometric, metabolic and bone changes in women with premature ovarian failure when using estradiol analogues

TLDR
The preliminary data suggest that estradiol is administered both transdermally and orally in young women with hypergonadotropic amenorrhea, with a significant time-treatment interaction effect.

Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis.

TLDR
Taller stature in late gonadectomised CAIS women suggests an oestrogen deficiency in these women prior to gonadectomy, and increased lower to upper body ratio in GD(XY) women compared with the other groups implies that these subjects have the greatest degree of oestrogens deficiency in puberty.

Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.

TLDR
In older men, aromatase inhibition increases testosterone levels, decreases estradiol levels, and appears to decrease BMD, and does not improve skeletal health in aging men with low or low normal testosterone levels.
...

References

SHOWING 1-10 OF 43 REFERENCES

Androgen-Receptor Blockade Does Not Impair Bone Mineral Density in Adolescent Females

TLDR
It is concluded that in adolescent women, peripheral hyperandrogenism is not associated with abnormal BMD; long-term treatment with flutamide, which blocks the androgen receptor, does not alter their BMD.

Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.

TLDR
Bone density increases during gonadal steroid replacement of GnRH-deficient men, particularly in men who are skeletally immature, and neither cortical nor trabecular bone density returned to normal levels.

Short‐term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty

TLDR
It is concluded that boys with constitutional delay of puberty have reduced BMC and BMD and the delay in statural and bone ages did not totally account for the decreased bone mass.

Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass.

TLDR
The bone mineral density was normal in premenopausal female patients as well as in male patients, showing that replacement doses of cortisone acetate do not affect bone mass, and the small amounts of androgens secreted by the adrenal cortex have a role in the maintenance of bone mass in normal postmenopausal women.

Flutamide‐mediated androgen blockade evokes osteopenia in the female rat

  • A. GouldingE. Gold
  • Biology, Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1993
TLDR
Findings support the view that androgens play an important role in preserving bone mass in the female rat, and it seems possible that antiandrogen drugs cause osteopenia in people as well as in the rat.

Androgens and bone.

TLDR
Observations in androgen-resistant animals clearly demonstrated that the sexual dimorphism of bone depends on the presence of a functional androgen receptor, and optimal peak bone mass seems related to an appropriately timed androgen secretion.

Bone and mineral metabolism in the androgen‐resistant (testicular feminized) male rat

TLDR
It is concluded that the absence of functional androgen receptors results in a decrease in radial and longitudinal bone growth and in a decreases in serum IGF‐I concentrations.

Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls.

TLDR
It is concluded that in normal girls, the pubertal growth spurt also results from the action of estrogens rather than of adrenal androgens, and physiologic estrogen replacement in hypogonadal females should be started at a bone age of about 11 years, and should not be delayed in the hope of achieving a greater mature height.

Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women.

TLDR
Nandrolone decanoate therapy increases bone formation, and the difference in the time-weighted mean rates of change between the two groups was significant.